Group 1 - City View Green Holdings Inc. announced a consolidation of its issued and outstanding common shares at a ratio of one (1) post-consolidated common share for every ten (10) pre-consolidated common shares [1][2][3] - The total number of outstanding shares will be reduced to approximately 45,681,347 common shares following the consolidation [1][3] - The name and symbol of the company will remain unchanged despite the share consolidation [2][4] Group 2 - All open orders will be canceled at the close of business on July 2, 2025, and dealers are advised to re-enter their orders considering the share consolidation [2][4] - Trading on a consolidated basis will commence on July 3, 2025, with the record date and anticipated payment date also set for July 3, 2025 [5] - The new CUSIP and ISIN for the consolidated shares are 178718201 and CA1787182015, respectively, while the old CUSIP and ISIN are 178718102 and CA1787181025 [5]

金十数据整理：中东局势跟踪（7月1日） 和谈情况： 1. 伊朗——①伊朗外交部：尚未决定与英国、法国和德国举行核谈判。②伊朗司法部门发言人表示，以 色列袭击伊朗造成的死亡人数已经上升到935人。 3. 美国——①美国总统特朗普计划于下周一在白宫会见以色列总理内塔尼亚胡。②白宫新闻秘书莱维 特：特朗普本人没有与伊朗进行过对话。中东问题特使威特科夫一直与伊朗方面保持联系。 其他： 1. 以军空袭加沙北部造成34人死亡。 跟踪中东局势动态 +订阅 2. 美总统特朗普签署行政令结束对叙利亚制裁。 3. 德国2025年将向乌克兰提供超90亿欧元援助。 4. 消息人士：伊拉克基尔库克空军基地遭到火箭袭击。 5. 以色列外长称有意与叙利亚和黎巴嫩建立正式外交关系。 6. 卡塔尔航空确认恢复对伊拉克、黎巴嫩、约旦和叙利亚的全部航班运营。 7. 美国国防部批准向以色列出售价值约5.1亿美元的弹药制导装置及弹药支持。 2. 以色列——以色列外长：以色列不会在任何和平协议中就戈兰高地进行谈判；周二，我们将在以色列 开始与欧盟对话。 ...

比特币直接画门，大涨大跌！昨日佩佩在文章《下周超级大变盘！比特币万点暴涨？SOL暴涨160，7月暴涨30%？这两个币要上天，知道就是赚到！》中 提示108000-109000期间可以做空，今早佩佩又在108700附近通知粉丝做空，暴赚74%！ 今早通知以太坊轻仓接空2500，2510止损 2560目标2450，2400,2350，ETH 稳健的可以止盈部分，公开和私聊都有发。 如果你昨天有看佩佩公众号或者问佩佩每日的开单策略，你应该和佩佩一样是吃到肉的，胜率大家可以明显看到，基本是全中胜率。现在每天吃香的喝辣 的！还没吃到肉的，佩佩带你布局，佩佩近期的大方向判断没有出错过。 BTC 文章来源：公众号佩佩梭哈 ETH 以太坊ETH 早盘突袭拉伸，再次冲击2520， 这是跌破2500后第二次反弹，主要是因为消息面带盘，炒作本周将迎来SEC对灰度数字大盘 ETF的最终审批 截止日期。 以太坊已形成结构性反转突破，当前构建回踩确认过程，关注FVG+OB重叠+前高区域2490–2480可多，上方留意2520-2550的供给区，2520测试两周，还 是没有上去阻力很大。 BTC日内在高点108888和低点107000区间 ...

Core Points - Thumzup Media Corporation has entered into a definitive agreement to purchase up to 1,083,333 shares of common stock at a price of $6.00 per share, aiming for gross proceeds of approximately $6.5 million before expenses [1] - The offering includes the issuance of 179,500 shares of Series C Convertible Preferred Stock, which are non-voting and have beneficial ownership limitations of 4.99% and 9.99% [1] - The net proceeds from the offering will be used for general corporate purposes and to explore accumulating other cryptocurrencies [1] Company Overview - Thumzup Media Corporation is focused on democratizing the social media branding and marketing industry, which is valued in the billions [4] - The company's flagship product, the Thumzup platform, allows users to earn cash for posting about participating advertisers on social media through a user-friendly app [4] - Advertisers can customize their campaigns using a programmatic advertiser dashboard, and payments to users are facilitated through digital payment systems like PayPal [4]

Core Viewpoint - Allbirds, Inc. has announced a comprehensive financing strategy aimed at optimizing working capital and enhancing financial flexibility to support long-term growth plans [1][2]. Financing Agreements - The company has established a new $75 million asset-based revolving credit facility, which includes a $50 million tranche and a $25 million accordion feature, replacing the previous $50 million facility [6]. - A sales agreement with TD Cowen allows the company to sell up to $50 million of Class A common stock through an At-the-Market (ATM) program [6]. - As of March 31, 2025, Allbirds reported $39.1 million in cash and cash equivalents, indicating a strong financial position [2]. Strategic Initiatives - The financing strategy supports Allbirds' initiatives to reignite product and marketing efforts, with new product launches expected in the coming weeks [2]. - The company plans to introduce over 15 new styles in its fall product lineup, focusing on modern design and unique materials [6]. - A new marketing strategy, under the "Allbirds by Nature" brand platform, aims to build long-term brand equity [6]. Operational Focus - Allbirds is committed to enhancing customer experience both online and in-store, with a store refresh program and a website redesign scheduled for July [6]. - The company emphasizes operational discipline and aims for long-term profitable growth while building durable value for shareholders [3].

Core Insights - Shoals Technologies Group, Inc. has released a webinar focused on Battery Energy Storage Systems (BESS) to educate stakeholders about the BESS market landscape and the company's solutions [1][2] Group 1: Webinar Details - The webinar aims to provide educational content for customers, investors, analysts, and other interested parties regarding the BESS market and Shoals' competitive position [2] - Featured speakers in the webinar include Mike Everson, BESS Account Executive, Matt Tractenberg, VP of Finance & Investor Relations, and Lindsey Williams, VP of Marketing & Communications [2] Group 2: Company Overview - Shoals Technologies Group is a leading provider of electrical balance of systems (EBOS) solutions for the energy transition market, recognized for its innovative technologies since its founding in 1996 [4] - The company focuses on enhancing installation efficiency, safety, system performance, and reliability for its customers in the renewable energy industry [4]

Core Points - Avicanna Inc. announced that all management nominees were elected as directors during the Annual General Meeting of Shareholders held on June 30, 2025 [1] - The shareholders approved the reappointment of Ramirez Jimenez International CPAs as auditors for the upcoming year [3] Company Overview - Avicanna is a biopharmaceutical company focused on developing, manufacturing, and commercializing plant-derived cannabinoid-based products for the global medical and pharmaceutical markets [4] - The company has a scientific platform that includes R&D and clinical development, leading to over thirty proprietary, evidence-based finished products [4] Product and Service Offerings - The RHO Phyto™ formulary offers a range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying cannabinoid ratios, currently available nationwide in Canada and expanding internationally [6] - MyMedi.ca is a medical cannabis care platform aimed at enhancing the patient journey, featuring a diverse product portfolio and bilingual pharmacist-led support programs [6] - Avicanna has developed a pipeline of proprietary cannabinoid-based candidates targeting unmet needs in dermatology, chronic pain, and neurological disorders [6] - The company’s subsidiary, Santa Marta Golden Hemp SAS, supplies high-quality CBD, THC, and CBG for various applications, forming part of Avicanna's supply chain [6]

Core Insights - Ecovyst Inc. released its 2024 Sustainability Report, highlighting progress towards sustainability goals and key metrics related to greenhouse gas emissions, energy, water, and waste [1][2] - The company emphasizes its commitment to developing cleaner technologies and supporting sustainable industries through its products and services, including sulfuric acid and catalysts [2][4] - Ecovyst aims to achieve specific sustainability goals by 2025 and 2030, with a focus on maintaining a zero OSHA recordables injury rate [2] Company Overview - Ecovyst Inc. is a global provider of advanced materials, specialty catalysts, virgin sulfuric acid, and sulfuric acid regeneration services, contributing to environmental sustainability [3][4] - The company operates two specialty businesses: Ecoservices, which provides sulfuric acid recycling and chemical waste handling, and Advanced Materials & Catalysts, which focuses on silica catalysts and zeolites for sustainable applications [4]

Core Viewpoint - Algernon Pharmaceuticals Inc. is amending the pricing and terms of its non-brokered private placement to raise gross proceeds of $1,000,000, adjusting the issue price for Common Units and Subscription Receipts [1][2]. Group 1: Offering Details - The amended issue price for Common Units is set at $0.06, down from $0.07, and for Subscription Receipts at $0.60, down from $0.70 [1]. - The Company anticipates that 25% of the Offering will be completed with Common Units and 75% with Subscription Receipts [1]. - The first tranche of the Offering has closed, raising gross proceeds of $621,000 through the issuance of 1,035,000 Subscription Receipts [5]. Group 2: Warrant Terms - Each Common Unit consists of one Common Share and one-half Common Warrant, with the full Common Warrant allowing the purchase of one Common Share at an initial exercise price of $0.15 for 12 months [2]. - The exercise price for Common Warrants will increase to $0.25 after the first anniversary and to $0.50 after the second anniversary [2][7]. - Each Preferred Unit consists of one Preferred Share and one-half Preferred Warrant, with an initial exercise price of $1.50 for 12 months, increasing to $2.50 and then to $5.00 in subsequent years [4][7]. Group 3: Use of Proceeds - Proceeds from the private placement will be used to advance the new Alzheimer's Disease program, cover general and administrative expenses, and for working capital [6]. - The Company plans to open its first U.S. Alzheimer's Disease clinic in Q4 2025 [6]. Group 4: Shareholder Approval and Dividends - The Company will expedite its annual meeting to seek shareholder approval for the issuance of Preferred Shares by the end of October 2025 [8]. - Preferred Shares will include a 10% annual dividend payable in Common or Preferred Shares at the discretion of the board [8].

Financial Performance - The company reported total expenses of $5,761,720 for the year ended December 31, 2024, a decrease of 49.1% from $11,304,857 in 2023[181]. - The net loss attributable to Qualigen Therapeutics, Inc. for the year ended December 31, 2024, was $6,346,795, compared to a net loss of $13,417,212 in 2023, reflecting a 52.8% improvement[181]. - The company experienced a loss from operations of $5,761,720 for 2024, compared to a loss of $11,304,857 in 2023, indicating a significant reduction in operational losses[181]. - The company reported a net loss per common share of $17.55 for the year ended December 31, 2024, compared to $132.25 in 2023, showing a substantial decrease in loss per share[181]. - The company recorded a loss of approximately $0.1 million on the disposal of discontinued operations in 2024, compared to a loss of approximately $0.6 million in 2023[202]. - The company recognized a loss of approximately $358,000 due to the issuance of new convertible debt in 2024, with no such loss reported in 2023[192]. Expense Management - General and administrative expenses decreased from $6.1 million in 2023 to $4.2 million in 2024, primarily due to a $0.8 million decrease in stock-based compensation and a $0.9 million decrease in payroll expenses[183]. - Research and development expenses decreased from $5.2 million in 2023 to $1.2 million in 2024, mainly due to a $2.9 million decrease in costs related to QN-302 and a $1.0 million decrease for Pan-RAS[184]. - The company implemented expense controls and slowed the development of therapeutic products starting in Q2 2024 due to financial constraints[167]. Cash Flow and Financial Position - As of December 31, 2024, the company had approximately $1.2 million in cash and net accounts payable exceeding $1.6 million, indicating a weak financial position[203]. - The company expects cash balances to fund operations only into the third quarter of 2025, raising substantial doubt about its ability to continue as a going concern[205]. - Operating activities used $6.3 million of cash in 2024, primarily due to a net loss of $6.3 million, compared to $10.3 million used in 2023[220][221]. - Net cash used by investing activities was approximately $1.9 million in 2024, primarily due to the issuance of $2.3 million in notes receivable to Marizyme[222]. - Net cash provided by financing activities was approximately $9.0 million in 2024, resulting from $4.6 million in proceeds from the sale of Series A-2 Preferred Stock and $3.1 million from the sale of common stock[224][226]. - The company reported a net increase in cash and restricted cash of $772,805 in 2024, compared to a decrease of $6,638,320 in 2023[219]. Agreements and Collaborations - The company advanced a total of $2,257,400 to Marizyme, Inc. during the year ended December 31, 2024, with accrued interest of $113,292 recognized[177]. - The company entered into a Co-Development Agreement with Marizyme, agreeing to pay up to $1,750,000 in funding and a $200,000 exclusivity fee[164]. - A Co-Development Agreement with Marizyme, Inc. includes a Funding Payment of up to $1,750,000 and an Exclusivity Fee of $200,000, with a 33% royalty on Net Sales of DuraGraft capped at double the Funding Payment[215]. - The company entered into a License Agreement with UCL Business Limited for a genomic quadruplex (G4)-selective transcription inhibitor drug development program, with an obligation to pay $100,000 upon the first patient dosing of QN-302[214]. Research and Development Focus - The company’s lead program, QN-302, is focused on treating cancers with a strong binding affinity to G-quadruplexes prevalent in cancer cells[162]. - The company’s Pan-RAS program targets mutated RAS genes, potentially effective in treating about 25% of all cancers, including pancreatic, colorectal, and lung cancers[163]. Credit and Liabilities - The estimated expected credit losses on the Marizyme Notes as of December 31, 2024, is $360,000, reflecting the uncertain nature of the debtor's financial condition[179]. - The company incurred a $0.4 million loss in expected credit losses on Marizyme Notes Receivable in 2024, with no credit losses reported in 2023[185]. - The estimated fair value of warrant liabilities increased to $0.3 million in 2024 from $0.1 million in 2023, resulting in a $0.4 million gain due to changes in fair value[186]. - The Marizyme Notes bear an interest rate of 18% per annum, with the option for Marizyme to pre-pay without penalty[217]. - The company recognized a non-cash loss on issuance of convertible debt of approximately $0.4 million in 2024[220]. Other Financial Activities - The company settled $395,000 of outstanding accounts payable for a gain of approximately $348,000 in 2024, with no similar settlements in 2023[198]. - The company has entered into various contracts for clinical trials and product development, which are generally cancelable on notice[218].